Updated on 31 August 2026
Understanding side-effects of radiotherapies
ASNR's permanent representative in Brussels at Autorité de Sûreté Nucléaire et de Radioprotection (ASNR)
Brussels, Belgium
About
ASNR's assets include:
-
Irradiation facilities: microbeam for intracellular irradiation, animal model irradiation, medical accelerator...
-
Animal testing laboratory licensed for the use of radioactive contaminants,
-
Modelling of ionising radiation sources, especially for personalised dosimetry,
-
Epidemiology,
-
Artificial Intelligence (image recognition, omics methods...),
-
Safety of high-risk organisations (Human and Social Sciences laboratory),
-
Comprehensive analytical laboratories licensed for the use of radioactive substances,
-
Active collaboration agreements with hospitals in the field of oncology and medical imaging.
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Organisation
Similar opportunities
Project cooperation
Including ionizing radiations in the exposome
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Bastien Poubeau
ASNR's permanent representative in Brussels at Autorité de Sûreté Nucléaire et de Radioprotection (ASNR)
Brussels, Belgium
Project cooperation
Nanomedicine for Drug Delivery, Imaging and Theranostics
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Brindusa Dragoi
Senior Scientist at Regional Institute of Oncology, Iasi
Iasi, Romania
Project cooperation
The Centre for Innovative Medicine (IMC)
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Tatjana Ivaskiene
General manager at State Research Institute Centre for Innovative Medicine
Vilnius, Lithuania